James Ulchaker

2 weeks ago | urologytimes.com | James Ulchaker |Hannah Clarke

In recent years, the treatment landscape for benign prostatic hyperplasia (BPH) has rapidly evolved with the rise of minimally invasive surgical therapies (MISTs). These innovative options not only offer greater convenience for patients, but also place a strong emphasis on preserving sexual function and enhancing overall quality of life. As the number of available MISTs continues to grow, treatment plans are becoming increasingly tailored to meet each patient’s unique needs.